There are nearly 50 million Alzheimer’s disease (AD) patients worldwide, 90% of whom develop behavioral and psychological symptoms of dementia (BPSD), which increase the mortality rate of patients, and impose an economic and care burden on families and society. As a neurotransmitter and neuromodulator, serotonin is involved in the regulation of psychoemotional, sleep, and feeding functions. Accumulating data support the importance of serotonin in the occurrence and development of BPSD. Studies have shown that reduction of serotonin receptors can increase depression and mental symptoms in AD patients. At present, there is no drug treatment for AD approved by the US Food and Drug Administration. Among them, agomelatine, as a new type of antidepressant, can act on serotonin 2 receptors to improve symptoms such as depression and anxiety. At present, research on BPSD is still in the preliminary exploratory stage, and there are still a lot of unknowns. This review summarizes the relationship between serotonin 2 receptors, agomelatine, and BPSD. It provides a new idea for the study of the pathogenesis and treatment of BPSD.

中文翻译：

---

5-羟色胺 2 受体、阿戈美拉汀以及阿尔茨海默病痴呆的行为和心理症状

全球有近 5000 万阿尔茨海默病 (AD) 患者，其中 90% 出现痴呆的行为和心理症状 (BPSD)，这增加了患者的死亡率，并给家庭和社会带来了经济和护理负担。作为一种神经递质和神经调节剂，5-羟色胺参与调节心理情绪、睡眠和喂养功能。越来越多的数据支持血清素在 BPSD 的发生和发展中的重要性。研究表明，血清素受体的减少会增加 AD 患者的抑郁和精神症状。目前，尚无美国食品和药物管理局批准的 AD 药物治疗。其中，阿戈美拉汀作为一种新型抗抑郁药，可作用于5-羟色胺2受体，改善抑郁、焦虑等症状。目前，BPSD的研究还处于初步探索阶段，还有很多未知数。本综述总结了 5-羟色胺 2 受体、阿戈美拉汀和 BPSD 之间的关系。为研究BPSD的发病机制和治疗提供了新的思路。